Systematic review of intralesional Cidofovir dosing regimens in the treatment of recurrent respiratory papillomatosis

Clamp, Philip; Saunders, M. W.

doi:10.1016/j.ijporl.2012.12.027

Cited by 28 publications

(9 citation statements)

References 49 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Other case series have reported partial to complete remission without any side effects in 24 of 26 patients at 6 months and 15 of 17 subjects at 1 year, respectively [3,4]. A systematic review in 2013 concluded that there is insufficient evidence from controlled trials to make reliable conclusions [5]. Notably, the dose, concentration, and frequency of administration were different among all case series.…”

Section: Discussionmentioning

confidence: 90%

Recurrent respiratory papillomatosis: the role of cidofovir

Tran

Galt

Bashirzadeh

2018

Respirology Case Reports

View full text Add to dashboard Cite

Recurrent respiratory papillomatosis (RRP) is a rare condition that affects the respiratory system. It is caused by human papilloma virus (HPV) infection. Usually infection and papilloma growth is limited to 6–12 months duration; however, some patients have persistent disease, resulting in long‐term symptoms and the need for recurrent intervention. Predominant symptoms include shortness of breath, reduced exercise tolerance and voice deterioration during flares. Current gold‐standard management is through resection via microdebrider, CO2 laser, cryotherapy, electrocoagulation, Nd: YAG laser or pulse‐dye laser. However, despite these therapies, approximately 20% of patients require adjuvant therapy. We discuss the use of intralesional cidofovir in the management of tracheal papillomatosis. Cidofovir’s mechanism of action involves incorporating into the virus DNA chain and therefore, inhibiting the viral DNA polymerization process and hence replication.

show abstract

Section: Discussionmentioning

confidence: 90%

Recurrent respiratory papillomatosis: the role of cidofovir

Tran

Galt

Bashirzadeh

2018

Respirology Case Reports

View full text Add to dashboard Cite

show abstract

“…Por ejemplo, existen variaciones importantes en cuanto a la concentración de cidofovir, el volumen, la dosis total, el número de administraciones, el intervalo entre los tratamientos y el tiempo de seguimiento. 39 Otras variables importantes entre los estudios son los desenlaces de interés analizados, que pueden incluir la tasa de remisión, la recurrencia de la enfer- 33 Serie de casos 4 niños 6 inyecciones cada 6-8 semanas Concentración 5 mg/mL Pransky 35 Serie de casos 10 niños Escala de Derkay 8-18 inyecciones cada 2 semanas Concentración 5 mg/mL Mandell 36 Casos y controles 7 niños (4 en grupo de cidofovir y 3 grupo control)…”

Section: Discussionunclassified

Eficacia del cidofovir intralesional en el tratamiento de papilomatosis respiratoria recurrente juvenil: una revisión sistemática

Ablanedo-Terrazas¹,

Barrera²,

Bross-Soriano³

et al. 2019

Anales Médicos De La Asociación Médica Del Centro Médico ABC

View full text Add to dashboard Cite

show abstract

“…Experience with the off-label use of the nucleotide analogue CDV and recent clinical trials indicate that CDV holds great promise as anti-cancer agent for the treatment of high-grade HPV+ carcinomas [16,17]. While CDV preferentially acts on E6/E7 viral oncogene-expressing cells [9], a recent study showed that the compound also inhibits primary glioma growth in human cytomegalovirus (HCMV)-infected as well as in non-infected patients [18], indicating that this compound may exert anti-tumor effects also in virus-independent neoplasms.…”

Section: Discussionmentioning

confidence: 99%

“…In fact, intralesional CVD has been one of the mainstays of adjuvant therapy in patients with recurrent respiratory papillomatosis (RRP) since 1998 [16]. Moreover, CDV has recently been evaluated in phase II clinical trials for HPV-associated high grade cervical and vulvar carcinoma and showed promise for topical treatment of cervical intraepithelial neoplasia grade (CIN) 2+ lesions [17].…”

Section: Introductionmentioning

confidence: 99%

The broad-spectrum anti-DNA virus agent cidofovir inhibits lung metastasis of virus-independent, FGF2-driven tumors

et al. 2014

View full text Add to dashboard Cite

The FDA-approved anti-DNA virus agent cidofovir (CDV) is being evaluated in phase II/III clinical trials for the treatment of human papillomavirus (HPV)-associated tumors. However, previous observations had shown that CDV also inhibits the growth of vascular tumors induced by fibroblast growth factor-2 (FGF2)-transformed FGF2-T-MAE cells. Here, we demonstrate that CDV inhibits metastasis induced by FGF2-driven, virus-independent tumor cells. Pre-treatment of luciferase-expressing FGF2-T-MAE cells with CDV reduced single cell survival and anchorage-independent growth in vitro and lung metastasis formation upon intravenous inoculation into SCID mice. This occurred in the absence of any effect on homing of FGF2-T-MAE cells to the lungs and on the growth of subconfluent cell cultures or subcutaneous tumors in mice. Accordingly, CDV protected against lung metastasis when given systemically after tumor cell injection. Lung metastases in CDV-treated mice showed reduced Ki67 expression and increased nuclear accumulation of p53, indicating that CDV inhibits metastasis by affecting single cell survival properties. The anti-metastatic potential of CDV was confirmed on B16-F10 melanoma cells, both in zebrafish embryos and mice. These findings suggest that CDV may have therapeutic potential as an anti-metastatic agent and warrants further study to select those tumor types that are most likely to benefit from CDV therapy.

show abstract

Systematic review of intralesional Cidofovir dosing regimens in the treatment of recurrent respiratory papillomatosis

Cited by 28 publications

References 49 publications

Recurrent respiratory papillomatosis: the role of cidofovir

Recurrent respiratory papillomatosis: the role of cidofovir

Eficacia del cidofovir intralesional en el tratamiento de papilomatosis respiratoria recurrente juvenil: una revisión sistemática

The broad-spectrum anti-DNA virus agent cidofovir inhibits lung metastasis of virus-independent, FGF2-driven tumors

Contact Info

Product

Resources

About